Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE NMO Study.

Martin W HümmertLouisa M SchöppeJudith Bellmann-StroblNadja SiebertFriedemann PaulAnkelien DuchowHannah PellkoferTania KümpfelJoachim HavlaSven JariusBrigitte WildemannAchim BertheleFlorian Then BerghMarc PawlitzkiLuisa Klotz Ingo KleiterMartin StangelStefan GingeleMartin S WeberJuergen H FaissRefik PulAnnette WalterUwe K ZettlMakbule SenelJan-Patrick Stellmann Vivien Häußler Kerstin HellwigIlya AyzenbergOrhan AktasMarius RingelsteinOlivia Schreiber-KatzCorinna Trebstnull null

Published in: Neurology (2022)

These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and to preserve quality of life.

Keyphrases

multiple sclerosis
electronic health record
big data
machine learning
bone marrow
drug administration
artificial intelligence